# PRISM-4D Validation Framework: Beyond Static Structure Prediction

## Executive Summary

AlphaFold3 revolutionized static structure prediction, but **proteins are not static**. Drug discovery increasingly depends on understanding:
- Cryptic pockets that only appear in certain conformations
- Allosteric sites accessed through conformational transitions
- Dynamic ensembles that define druggability

**PRISM-4D's NOVA engine directly targets this gap.**

This validation framework demonstrates PRISM-4D's capabilities where AlphaFold3 cannot compete:

| Capability | AlphaFold3 | PRISM-NOVA |
|------------|-----------|------------|
| Static structure | ✅ Excellent | ✅ Good |
| Conformational ensemble | ❌ Single snapshot | ✅ Full ensemble |
| Cryptic pocket detection | ❌ Cannot | ✅ TDA-guided |
| Apo-holo transitions | ❌ Cannot | ✅ Goal-directed |
| Dynamics (RMSF) | ❌ Cannot | ✅ HMC sampling |

## Validation Tiers

### Tier 1: ATLAS Ensemble Recovery (Dynamics Validation)

**What**: Recover experimentally-determined conformational ensembles from NMR/MD

**Why**: Proves PRISM-NOVA samples biologically-relevant conformations, not random noise

**Benchmark**: ATLAS database (>10,000 proteins with ensemble data)

**Metrics**:
- Root Mean Square Fluctuation (RMSF) correlation with experiment
- Pairwise RMSD distribution match
- Principal Component overlap (cosine similarity of PC1-3)
- Lindemann criterion for flexibility regions

**Pass Criteria**:
- RMSF Pearson r > 0.7 (vs AF3 ~0.2-0.3)
- PC1-3 overlap > 0.8

### Tier 2: Apo-Holo Transition Prediction (Cryptic Pocket Validation)

**What**: Starting from apo structure, predict holo conformation with ligand-binding site exposed

**Why**: This is THE core capability for cryptic pocket drug discovery

**Benchmark**: Curated set of 50+ proteins with known apo-holo pairs:
- Different apo and holo crystal structures
- Cryptic pocket only visible in holo
- Blind: holo structure NOT used in prediction

**Test Cases** (Selected):

| Protein | PDB Apo | PDB Holo | Cryptic Site | Difficulty |
|---------|---------|----------|--------------|------------|
| IL-2 | 1M47 | 1M48 | Groove | Medium |
| PTP1B | 2HNP | 1T49 | Allosteric C-term | Hard |
| KRAS G12C | 4OBE | 6OIM | Switch-II pocket | Hard |
| BCL-xL | 1MAZ | 2YXJ | BH3 groove | Medium |
| MDM2 | 1Z1M | 4ERE | p53-binding | Medium |
| TEM-1 β-lactamase | 1BTL | 1TEM | Omega loop | Hard |
| HIV-1 RT | 1DLO | 1RT1 | NNRTI pocket | Hard |
| HCV NS3/4A | 1A1R | 1DY8 | Allosteric | Hard |

**Metrics**:
- Pocket RMSD (target residues only) < 2.0 Å
- SASA gain in pocket region > 80% of experimental
- TDA Betti-2 detection of void formation
- Time to transition (efficiency)

**Pass Criteria**:
- >70% of targets with pocket RMSD < 2.5 Å
- >80% of targets with correct pocket topology (Betti-2 match)

### Tier 3: Retrospective Blind Validation (Pharma Relevance)

**What**: Predict druggability of sites that led to actual drugs

**Why**: The only validation that matters for pharma - did you find what became a drug?

**Protocol**:
1. Start from structure BEFORE drug was discovered
2. Run PRISM-NOVA to generate ensemble
3. Score pockets for druggability
4. Compare against actual drug binding site
5. Blind: drug structure NOT used in prediction

**Test Cases by Therapeutic Area**:

#### Oncology (Kinase Inhibitors + Beyond)

| Target | Drug | Approval | Site Type | Validation |
|--------|------|----------|-----------|------------|
| KRAS G12C | Sotorasib | 2021 | Cryptic Switch-II | Blind |
| BTK C481 | Ibrutinib | 2013 | Covalent pocket | Blind |
| BCR-ABL | Imatinib | 2001 | DFG-out pocket | Blind |
| MEK1/2 | Trametinib | 2013 | Allosteric | Blind |
| SHP2 | TNO155 | Phase 3 | Tunnel site | Blind |

#### Metabolic Diseases

| Target | Drug/Compound | Status | Site Type | Validation |
|--------|---------------|--------|-----------|------------|
| PTP1B | Trodusquemine | Phase 2 | Allosteric C-term | Blind |
| PCSK9 | Evolocumab mechanism | Approved | Cryptic EGF-A | Blind |
| GLP-1R | Semaglutide pocket | Approved | Transmembrane | Blind |
| GPR40 | TAK-875 site | Discontinued | Allosteric | Blind |

#### Infectious Disease

| Target | Drug | Status | Site Type | Validation |
|--------|------|--------|-----------|------------|
| HIV-1 RT | Rilpivirine | Approved | NNRTI pocket | Blind |
| HCV NS3 | Glecaprevir | Approved | Allosteric | Blind |
| HCV NS5A | Ledipasvir | Approved | Dimer interface | Blind |
| SARS-CoV-2 Spike | --- | Research | RBD cryptic | Blind |
| HIV Integrase | Dolutegravir | Approved | Active site flex | Blind |

**Metrics**:
- Site discovery rate: % of drugs where we find the binding site
- Ranking: Is the actual drug site in top-3 scored pockets?
- Druggability score correlation with actual ΔG

**Pass Criteria**:
- >80% site discovery rate
- >70% in top-3 ranking
- Druggability-ΔG correlation r > 0.6

### Tier 4: Novel Cryptic Site Discovery Benchmark (PRISM-Defined)

**What**: Define a NEW benchmark for cryptic site prediction

**Why**: Existing benchmarks don't adequately test dynamics-based discovery

**Design**:
1. Curate 100 proteins with experimentally-confirmed cryptic sites
2. Split: 80 training (for method development), 20 held-out (blind)
3. Metrics designed for dynamics:
   - Time to first pocket opening
   - Stability of open state
   - Reversibility (can it close again?)
   - Ligandability score

**Novel Metrics We Define**:
- **Topological Transition Time (TTT)**: Steps until Betti-2 changes
- **Pocket Stability Index (PSI)**: Fraction of ensemble with pocket open
- **Conformational Entropy Gain (CEG)**: ΔS from apo to holo ensemble
- **Dynamic Druggability Score (DDS)**: Composite of above + binding site features

## AlphaFold3 Comparison Protocol

To demonstrate PRISM-NOVA's advantages, we run head-to-head comparisons:

### Experiment 1: Ensemble Diversity

**Setup**:
- AF3: Generate 5 structure predictions with different seeds
- PRISM-NOVA: Generate 1000-step trajectory, cluster into 5 representatives

**Measure**:
- Pairwise RMSD between predictions
- Coverage of experimental ensemble (if available)
- Pocket diversity

**Expected Result**: AF3 gives ~same structure 5 times; PRISM-NOVA gives diverse ensemble

### Experiment 2: Cryptic Pocket Detection

**Setup**:
- Input: Apo structure only
- AF3: Predict structure
- PRISM-NOVA: Run dynamics, detect pockets via TDA

**Measure**:
- Does cryptic pocket appear?
- SASA of known binding site
- Betti-2 (void detection)

**Expected Result**: AF3 returns apo-like structure; PRISM-NOVA finds cryptic pocket

### Experiment 3: Binding Site Flexibility

**Setup**:
- Input: Holo structure with ligand removed
- AF3: Predict structure
- PRISM-NOVA: Run dynamics

**Measure**:
- Does binding site collapse (as it should)?
- Time to collapse
- Can it re-open?

**Expected Result**: AF3 keeps binding site artificially open; PRISM-NOVA shows realistic collapse

## Implementation Plan

### Phase 1: Data Curation (Week 1)

```
data/validation/
├── atlas/
│   ├── ensembles/          # NMR ensembles, MD trajectories
│   └── targets.json        # Metadata
├── apo_holo/
│   ├── pairs/              # Apo-holo PDB pairs
│   └── targets.json        # Pocket definitions
├── retrospective/
│   ├── oncology/
│   ├── metabolic/
│   ├── infectious/
│   └── targets.json        # Drug binding sites (blind)
└── novel_benchmark/
    ├── training/           # 80 proteins
    ├── test/               # 20 proteins (held-out)
    └── annotations.json
```

### Phase 2: Benchmark Harness (Week 2)

```rust
// prism-validation/src/lib.rs
pub trait ValidationBenchmark {
    fn name(&self) -> &str;
    fn run(&self, nova: &PrismNova, target: &Target) -> BenchmarkResult;
    fn score(&self, result: &BenchmarkResult) -> ValidationScore;
    fn compare_af3(&self, result: &BenchmarkResult, af3_result: &Af3Result) -> Comparison;
}

pub struct AtlasBenchmark { /* ... */ }
pub struct ApoHoloBenchmark { /* ... */ }
pub struct RetrospectiveBenchmark { /* ... */ }
pub struct NovelCrypticBenchmark { /* ... */ }
```

### Phase 3: Run Validation (Week 3-4)

1. Run all benchmarks
2. Generate comparison figures
3. Statistical analysis
4. Write report

### Phase 4: Publication-Ready Results (Week 5)

- Figures for paper
- Supplementary data
- Reproducibility scripts
- Public benchmark release

## Success Criteria Summary

| Benchmark | Metric | Target | AF3 Expected |
|-----------|--------|--------|--------------|
| ATLAS Ensemble | RMSF correlation | >0.7 | 0.2-0.3 |
| Apo-Holo | Pocket RMSD <2.5Å | >70% | <10% |
| Retrospective | Site discovery | >80% | ~30% |
| Novel | TTT efficiency | Top quartile | N/A |

## Why This Validation Matters

1. **Scientific Rigor**: Multi-tier validation with blind protocols
2. **Pharma Relevance**: Retrospective validation against real drugs
3. **Clear Differentiation**: Head-to-head AF3 comparison on dynamics
4. **Novel Contribution**: Define new benchmarks for the field
5. **Reproducibility**: All data and code publicly available

This positions PRISM-4D not as "another structure predictor" but as **the platform for dynamic, cryptic, and allosteric drug discovery** - the frontier where AlphaFold cannot go.
